Compare Mesoblast Limited (MESO) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Valero Energy Corporation — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Valero Energy Corporation trades at $311 (market cap $93.03B). The key difference: Valero Energy Corporation is far larger — about 42.9× Mesoblast Limited's market cap, and Valero Energy Corporation pays a 1.53% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | VLO | |
|---|---|---|
Market Cap | $2.17B | $93.03B |
Sector | Technology | Energy |
52-Week High | $20.96 | $313.31 |
52-Week Low | $12.88 | $131.77 |
Enterprise Value | $2.17B | $98.79B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Valero Energy (VLO) trades at $314.81, up 1.67% on the day, with strong technical momentum and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.22 surpassing expectations of $3.16. Revenue declined to $122.69 billion in 2025, but net income margin held at 3.37%, supported by robust refining margins. Recent news highlights strong fuel demand and elevated crack spreads benefiting Valero's outlook.
The outlook remains positive given earnings beats, analyst buy ratings (55.55%), and refining margin tailwinds. However, declining revenue trends, high RSI levels suggesting overbought conditions, and exposure to volatile energy markets pose risks. The consensus price target of $276.22 implies potential downside from current levels, requiring careful monitoring of Q2 2026 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
